

ondine



For Immediate Release

**Ondine demonstrates high Periowave™ efficacy in key tissue-invasive pathogen
-abstract to be presented at IADR conference, New Orleans-**

Vancouver, Canada – March 23, 2007 - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) today announced presentation of a late-breaking abstract at the prestigious International Association of Dental Research (IADR) annual meeting in New Orleans. This publication showed that the Periowave™ photodisinfection system is capable of eradicating one of the most elusive and difficult to kill periopathogens, *Actinobacillus actinomycetemcomitans* (*Aa*). *Aa* is a Gram-negative facultative anaerobe that infects periodontal tissues themselves rather than dental biofilms, making the bacterium extraordinarily difficult to eradicate with routine mechanical debridement.

“In a recent *in vitro* study, Periowave™ proved capable of killing up to 99.999% of biofilm-based periopathogens such as *P. gingivalis* and *F. nucleatum* in both planktonic and biofilm culture, and eradicating over 99% of *Aa* in 60 seconds,” said Dr. Cale Street, Director of Research for Ondine Research Laboratories. “This was an important and gratifying outcome, because it has been known for many years that *Aa* is implicated in cases where disease is unresponsive to standard mechanical debridement. This finding may explain why Periowave™ improved outcomes in several clinical cases where routine mechanical debridement as well as antibiotic therapy had been carried out for years, with only marginal results.”

As previously released, three other poster abstracts based on the clinical trial conducted by Loma Linda University will also be presented at the conference by the Principle Investigators of the study.

The 85th Annual IADR/AADR conference runs from March 21-24th, 2007 in New Orleans and is expected to attract 5000 dental researchers from around the world who are dedicated to the prevention and treatment of oral and dental diseases.

About Periowave™ and Photodisinfection (PDD)

Periowave™ is a Photodisinfection system developed by Ondine that utilizes low-intensity lasers and wavelength-specific, light-activated compounds to specifically target and destroy microbial pathogens and reduce the symptoms of disease. The compounds are generally topically applied and one or more lasers are used to activate the compounds and complete the disinfection. The Photodisinfection technologies were developed by Professor Michael Wilson and colleagues at the Eastman Dental Institute, University College London, and licensed to Ondine by UCL Biomedica PLC, University College London. Additional information about Periowave™ is available at www.periowave.com.

About Ondine Biopharma Corporation:

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on creating and commercializing leading-edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance.

The Company is headquartered in Vancouver, British Columbia, Canada, with a research laboratory in Redmond, Washington, USA, a sales and marketing subsidiary in York, Pennsylvania, and an international office in St Michael, Barbados. For additional information, please visit the Company's website at: www.ondinebiopharma.com.

Forward-Looking Statements:

Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's filings.

For further information please contact:

Carolyn Cross	Christina Bessant
President and Chief Executive Officer	Investor Relations
Ondine Biopharma Corporation	The Equicom Group Inc.
(604) 669-0555	(416) 815-0700 ext. 269
ccross@ondinebiopharma.com	cbessant@equicomgroup.com